Nexalin Technology (Nexalin Technology) EV-to-EBIT : -0.34 (As of May. 31, 2024)

View and export this data going back to 2022. Start your Free Trial

What is Nexalin Technology EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Nexalin Technology's Enterprise Value is $2.07 Mil. Nexalin Technology's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-6.03 Mil. Therefore, Nexalin Technology's EV-to-EBIT for today is -0.34.

The historical rank and industry rank for Nexalin Technology's EV-to-EBIT or its related term are showing as below:

NXL' s EV-to-EBIT Range Over the Past 10 Years
Min: -3.64 Med: -0.34 Max: 2.14
Current: -0.34

During the past 4 years, the highest EV-to-EBIT of Nexalin Technology was 2.14. The lowest was -3.64. And the median was -0.34.

NXL's EV-to-EBIT is ranked worse than
100% of 449 companies
in the Medical Devices & Instruments industry
Industry Median: 19.76 vs NXL: -0.34

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Nexalin Technology's Enterprise Value for the quarter that ended in Mar. 2024 was $8.27 Mil. Nexalin Technology's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-6.03 Mil. Nexalin Technology's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -72.95%.

Nexalin Technology EV-to-EBIT Historical Data

The historical data trend for Nexalin Technology's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nexalin Technology EV-to-EBIT Chart

Nexalin Technology Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

0.43

-0.01

Nexalin Technology Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-EBIT	Get a 7-Day Free Trial									-0.40	-0.89	0.03	-0.01	-1.37

Competitive Comparison of Nexalin Technology's EV-to-EBIT

For the Medical Devices subindustry, Nexalin Technology's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nexalin Technology's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Nexalin Technology's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Nexalin Technology's EV-to-EBIT falls into.

Nexalin Technology EV-to-EBIT Calculation

Nexalin Technology's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	2.073	/	-6.031
	=	-0.34

Nexalin Technology's current Enterprise Value is $2.07 Mil.
Nexalin Technology's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.03 Mil.

Nexalin Technology (NAS:NXL) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Nexalin Technology's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 )	=	EBIT	/	Enterprise Value (Q: Mar. 2024 )
	=	-6.031	/	8.267184
	=	-72.95 %

Nexalin Technology's Enterprise Value for the quarter that ended in Mar. 2024 was $8.27 Mil.
Nexalin Technology's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.03 Mil.

Nexalin Technology EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Nexalin Technology's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Nexalin Technology (Nexalin Technology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nexalin Technology Inc (NAS:NXL) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

1776 Yorktown, Suite 550, Houston, TX, USA, 77056

Website

https://www.nexalin.com

Nexalin Technology Inc design and develop innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy.

Executives

Marilyn Elson	10 percent owner, officer: Ms. Elson serves as CFO	32 CAMLET COURT, ROSELAND NJ 07068
Rick Morad	director	6331 CHAGRIN RIVER ROAD, BENTLEYVILLE OH 44022
Mark White	director, officer: President/CEO	1776 YORKTOWN STREET, SUITE 550, HOUSTON TX 77056
David Owens	director, officer: Chief Medical Officer	4545 HARRIS TRAIL NW, ATLANTA GA 30327
Alan Kazden	director	3435 CONSUELO DRIVE, CALABASAS CA 91302
Leonard Osser	other: Spouse
Ben Hu	director	7021 EDGERTON ROAD, NORTH ROYALTON OH 44133